Eisbach Bio GmbH’s Post

Immuno-Oncology in vivo studies are complex and require meticulous planning and execution. 📕 Read our new blog to enhance your immuno-oncology preclinical research with 5 essential steps, from selecting tumor models to analyzing drug mechanisms. #ImmunoOncology #IO #CancerResearch #Oncologyresearch #cancer #oncology #invivo #exvivo #invivostudy #exvivostudy #syngeneicmodels #humanizedmodels #syngeneic #humanized https://hubs.li/Q02Drkk50

I am thrilled to announce publication of the design and preclinical evaluation of our lead molecule MTX-531 in Nature Cancer. This first-in-class kinase inhibitor was rationally designed to selectively co-target both PI3K and EGFR. MTX-531 elicits a high incidence of durable tumor regressions and increased lifespan exceeding 500% in multiple preclinical models. Its exceptional efficacy is enabled by a favorable tolerability profile, including lack of hyperglycemia commonly seen with panPI3K inhibitors. The advancement of MTX-531 reflects MEKanistic’s commitment to innovative approaches to address the critical challenge of adaptive resistance to molecular targeted therapies.  The scientific paper can be accessed at the following link: https://lnkd.in/gW6zpcrk.   

#cancerresearch #oncology #cancertreatment https://lnkd.in/gwvWCDZR Researchers have discovered ways to convert inhibitor-style targeted #cancer #drugs into small molecules known as #degraders, which help destroy cancer-promoting proteins in cells. The scientists selected molecules known to inhibit certain proteins and modified them in various ways to convert them into protein degraders, which break down the protein. Other scientists can now replicate this novel approach to develop and optimise a range of protein degraders. In the long term, this may help with making existing cancer treatments more effective and creating new treatments to target different proteins involved in cancer, including proteins that may previously have been considered ‘undruggable’.

We are pleased to announce that our AI-designed #molecularglue drug pipeline, MRANK-103, has successfully advanced to the IND-Enabling stage. This marks the fifth preclinical candidate (PCC) designated by 德睿智药 MindRank. Leveraging our AI-driven molecular glue rational design platform ProtaG™, MRANK-103 targets the #MYC signaling pathway and is designed to regulate eukaryotic translation and transcription factors.  This is a significant milestone in our fight against challenging cancers such as CDK4/6-resistant breast cancer, colorectal cancer, lung cancer, and gastric cancer—areas where current treatments are inadequate. We look forward to sharing more updates as we progress! #AI #artificialintelligence #DrugDiscovery #Oncology #Biotech #PrecisionMedicine #HealthcareInnovation

https://lnkd.in/dGPxU8_T 🔬 Exciting News Alert! 🎉 Thrilled to share that our latest research article in Molecular Cancer: We identified a novel lncRNA transcript, upregulated in NRAS/MAPK-dependent melanoma, and named it T-RECS (yes!). Our findings demonstrate that T-RECS inhibition with antisense oligonucleotides (ASOs) effectively reduces melanoma cell growth and induces apoptosis, with minimal impact on normal melanocytes. Moreover, our preclinical studies show promising results in suppressing tumor growth without toxicity. #MelanomaResearch #cancertreatment

I am honored and excited to join the Shasqi team to bring the systemic targeted CAPAC technology to patients! It has been a privilege to contribute to the design, characterization, and development of ADCs over the last 12 years. In this time, we helped realize the benefit of ADCs for cancer patients and also learned their shortcomings and opportunities to innovate. ADCs are often dose-limited by target-independent toxicities. Consistent with this, less than 1% of the ADC dose is catabolized by the tumor and the remaining 99% is catabolized by normal tissues leading to toxicities. We have known this for years and haven't been able to address it on the ADC platform. Smaller format direct conjugates are an intriguing solution, but they are plagued by renal resorption, catabolism in the proximal tubule, and recirculation of active payload leading to toxicities. We need to separate the targeting modality from the payload. Deliver the targeting modality, rapidly clear that not bound to antigen, deliver the payload and activate it only at the site of the antigen-bound targeting modality. This is exactly how the CAPAC technology works where it leverages the power of bioorthogonal Click chemistry to activate drug at the site of the antigen-bound targeting modality. An opportunity to help develop a technology that can significantly increase that 1% tumor catabolism is very exciting!

Oncoteq, a clinical stage biotech company specializing in innovative cancer treatments, today announces its second in-licensing deal as it obtains a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment. The first-in-class compound TEQ103 (formerly SERA2) is a selective estrogen receptor activator, which specifically targets cancer cells expressing estrogen receptor alpha and in mouse models induces complete regression of tumors that are resistant to current treatments. The deal represents Oncoteq’s second in-licensing of a potential first-in-class or best-in-class cancer treatment following its transaction with Merck KGaA in 2022. The company will continue to seek opportunities with which to expand its growing oncology-focused pipeline. Read more in the attached press release. Cureteq AG Partex NV Assay.Works #oncology #biotechnology #artificialintelligence #breastcancer

I am very thankful and grateful for the major news that was released today regarding a novel, drug molecule (ErSo) originally developed by the University of Illinois Urbana-Champaign and David Shapiro & his team to treat breast cancer. https://lnkd.in/exmQumba The results of numerous animal studies have been nothing short of spectacular. Please see today's message and press release from Oncoteq AG the Switzerland-based clinical stage biotech company that is now responsible for taking this drug to clinical trial under the name TEQ103. I haven't shared with my wider professional network that my daughter, Tiffany O'Donnell, succumbed to metastatic breast cancer on August 5, 2023, at the age of 43, following a 10-year battle with this disease. A disease that is still claiming over 350,000 lives every year. It's been a devastating loss that will forever change our lives in ways big and small. We miss her dearly. I have personally leaned in to help in some small way Systems Oncology and Spyro Mousses over the past year, and now Oncoteq AG to reduce the friction with capital, access to resources and to knock down any barriers to seeing TEQ103 get to Phase I clinical trial and first in humans dosages as soon as feasible. Mads Dalsgaard and his team at Oncoteq AG are first rate scientists and biotech developers who leverage an AI-based platform to identify the optimal applications of a given molecule and de-risk clinical development. I'm very optimistic TEQ103 has the potential to be a game changer in the treatment of ER+ breast cancer (~80% of breast cancers) to extend lives and provide durable long-term outcomes. Please private message me if you're interested in learning more about Oncoteq AG and TEQ103. #curecancer #metavivor #breastcancer #innovation #cancermoonshot

Supercomputing at Lawrence Livermore National Laboratory in partnership with BridgeBio has helped produce a drug that has potential to treat "undruggable" cancer--and it's just gone into clinical trials for patients with non-small cell lung cancer. Felice Lightstone speaks more about high-powered computing and how it can both shorten timelines and reduce the cost of producing life-saving treatments in the article I wrote for The Independent. https://lnkd.in/gJjXdcr4

Clasp Therapeutics launches with a groundbreaking $150 million in financing, signaling a new era in cancer treatment. Here's why this matters: 1. **Next-Gen Cancer Therapy**: Clasp's precision immuno-oncology approach targets oncogenic mutations with unparalleled specificity, potentially revolutionizing cancer treatment. 2. **Renowned Leadership**: Backed by top experts like Bert Vogelstein and Drew Pardoll, Clasp is poised to make significant strides in cancer immunotherapy. 3. **Broad Support and Impact**: With substantial financing and a promising TCE platform, Clasp is well-positioned to address a wide range of challenging tumor types. For more details, check out the full article [here](https://lnkd.in/g9nWyKMN).